Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly transparent PAA-functionalized porous silica coatings with underwater superoleophobicity and oil-fouling resistance.

RSC advances·2026
Same author

Genome-wide identification and analysis of GATA genes family in maize reveals involvement of ZmGATA17 in salt stress tolerance.

Gene·2026
Same author

Tumor-associated M2 macrophages promote prostate cancer invasion through the M-CSF-PCLAF pathway.

PloS one·2026
Same author

The identification of counterfeit high-quality edible oil using EEM fluorescence spectroscopy based on GA-optimized 2D-LDA.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

Integrated control of MRSA biological contamination via SarA-targeting γ-mangostin: A green natural antimicrobial strategy.

Journal of hazardous materials·2026
Same author

Astrocyte-derived IL-17A facilitates angiogenesis following ischemia-like injury via an IL-6-dependent STAT3-VEGF signaling cascade.

Behavioral and brain functions : BBF·2026

Related Experiment Video

Updated: Sep 10, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Poricoic Acid A, an Active Ingredient Extracted From Poria cocos, Inhibits Lung Cancer Cell Growth by Suppressing

Xueni Sun1,2,3, Haiyang Jiang2, Shuyi Ren2

  • 1Department of Gastrointestinal and Pancreatic Surgery, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Zhejiang, Hangzhou, China.

Phytotherapy Research : PTR
|August 27, 2025
PubMed
Summary

Poricoic acid A (PAA), a compound from Poria cocos mushroom, effectively inhibits lung cancer growth by inducing apoptosis and cell cycle arrest. This natural compound shows promise as a safe and effective lung cancer therapeutic agent.

Keywords:
MEK/ERK signaling pathwayanticancer activitylung cancerporicoic acid A

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Experiment Videos

Last Updated: Sep 10, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Area of Science:

  • Pharmacology
  • Oncology
  • Natural Products Chemistry

Background:

  • Lung cancer remains a major clinical challenge requiring novel therapeutic strategies.
  • Poricoic acid A (PAA), derived from Poria cocos, exhibits potential antitumor properties.
  • The therapeutic efficacy, mechanism, and safety of PAA for lung cancer require thorough investigation.

Purpose of the Study:

  • To investigate the therapeutic potential of Poricoic acid A (PAA) against lung cancer.
  • To elucidate the mechanism of action of PAA in inhibiting lung cancer progression.
  • To evaluate the safety profile of PAA in preclinical models.

Main Methods:

  • In vitro studies involved treating H460 and H1299 lung cancer cells with PAA.
  • Assays included CCK-8, colony formation, and flow cytometry to assess cell viability, proliferation, apoptosis, and cell cycle.
  • In vivo studies utilized mouse models to evaluate tumor inhibition and organ safety.

Main Results:

  • PAA significantly inhibited lung cancer cell growth and proliferation in vitro.
  • PAA induced apoptosis and G2/M phase cell cycle arrest in lung cancer cells.
  • PAA demonstrated low toxicity and minimal adverse effects on primary organs in vivo.
  • PAA was found to directly target MEK1/2, downregulating the MEK/ERK signaling pathway.

Conclusions:

  • Poricoic acid A exhibits significant therapeutic potential against lung cancer.
  • PAA acts by targeting MEK1/2 and inhibiting the MEK/ERK pathway.
  • PAA presents a promising, safe, and effective natural compound for future clinical investigation in lung cancer treatment.